Summary
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
History
Maravai LifeSciences was founded in 2002, with a vision of providing superior reagents and services to the scientific community. Since that time, the company has continued to grow, expanding its product line and increasing its global reach. Today, Maravai LifeSciences is a trusted partner to researchers and manufacturers around the world.
Mission
Maravai LifeSciences seeks to become a leader in the life science industry by providing superior products and services with a commitment to excellence and innovation.
Vision
Maravai LifeSciences is dedicated to enabling the life science community to conduct world-class research and manufacture quality products, while advancing their knowledge and understanding of the various disciplines of the life science industry.
Key Team
Ms. Christine Dolan (Chief Operating Officer of Biologics Safety Testing)
Mr. Brian Neel (Chief Operating Officer of Nucleic Acid Production)
Dr. Peter Michael Leddy Ph.D. (Exec. VP & Chief Admin. Officer)
Ms. Debra Hart (Sr. Director of Investor Relations)
Ms. Doreen Pippen (VP of Marketing)
Recognition and Awards
Maravai LifeSciences has been recognized as one of the Fastest Growing Companies in North America. The company has also won multiple awards for its commitment to quality, customer service, and innovation.
References
United States 